Alan MacIntosh
Partner and Co-Founder @ Real Ventures
Montréal, Canada
Alan MacIntosh is a seed investor at Real Ventures in Montréal focused on Software and Health Care. Alan MacIntosh has extensive international experience in innovative technology businesses beginning in Europe in oil exploration with Schlumberger, data networking with Hewlett Packard and entering mobile in 1990 with Canada’s Telesystem group. At TIW, he established mobile operations in eight countries and in 1997 co-founded GSM Capital, the firstglobal wireless venture fund with offices in Boston, London and Hong Kong.In 2004, Alan co-founded Acta Wireless and, in 2008, Real Ventures which is Canada's most active venture fund with more than 100 investments in mobile and web tech start-ups.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries Alan MacIntosh invests in
Stages Alan MacIntosh invests in
Countries Alan MacIntosh invests in
Round sizes
Round size
- Seed
- $200k–$3.5M
- Series A
- $4M–$12M
- Series B
- $9.3M–$20M
Investment Focus
Industry
- Software 3 (21%)
- Health Care 3 (21%)
- Machine Learning 3 (21%)
- Medical 2 (14%)
- Medical Device 2 (14%)
Stage
- Seed 5 (36%)
- Series A 5 (36%)
- Series B 2 (14%)
- Debt Financing 1 (7%)
- Convertible Note 1 (7%)
Country
- Canada 6 (43%)
- United Kingdom 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
XpertSea
|
XpertSea is a Canadian technology company that's transforming how the global aquaculture industry farms seafood to help feed the world. Combining smart aquaculture equipment with a farm management platform, our collaborative solution uncovers actionable insights driven by artificial intelligence. These insights enable farmers and industryexperts to optimize feed efficiency, reduce environmental waste, take preventive actions against diseases and use data to bring transparency and knowledge to the entire supply chain. With customers in over 50 countries, we’re using Canadian ingenuity to make aquaculture profitable and sustainable. | $20M / Series B / Aug 10, 2021 | |
BIOS
|
BIOS Health uses data-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer forprecision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life.Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology and medicine. Advisors include Oxford University Professors David Paterson and Tim Denison, CEO of Candel Therapeutics Paul Peter Tak, and IQVIA VP of Genomic and Precision Medicine Joanne Hackett (Chair of the BIOS Board). | $4.5M / Seed / Dec 04, 2018 | |
Algolux
|
Algolux is an award-winning AI software company delivering the industry’s most robust and scalable perception for all conditions, addressing both existing cameras and new designs through cloud-based tools and embedded software. The company was founded on groundbreaking research at the intersection of deep learning, computer vision, andcomputational imaging. Our computer vision and image optimization solutions address the mission-critical issue of safety for automotive ADAS, autonomous vehicles, fleets, autonomous mobile robots, and video security. | $10M / Series A / May 01, 2018 | |
|
XpertSea
|
XpertSea is a Canadian technology company that's transforming how the global aquaculture industry farms seafood to help feed the world. Combining smart aquaculture equipment with a farm management platform, our collaborative solution uncovers actionable insights driven by artificial intelligence. These insights enable farmers and industryexperts to optimize feed efficiency, reduce environmental waste, take preventive actions against diseases and use data to bring transparency and knowledge to the entire supply chain. With customers in over 50 countries, we’re using Canadian ingenuity to make aquaculture profitable and sustainable. | $7.2M / Series A / Apr 17, 2018 | |
Swift Medical
|
Swift Medical is a digital wound care technology to improve the prevention, treatment, and management of wounds. From Capture to Claim: The world's most advanced and comprehensive wound care management software for the healthcare enterprise. Precise, consistent measurement, instant documentation and wound progression images with a smartphone. | $11.6M / Series A / Mar 29, 2018 | |
FitMyFoot
|
Wiivv (pronounced weave) is a technology company transforming footwear, apparel, and wearables for every human body, so that you can move and live your best. Wiivv Insoles and Sandals are created uniquely for you, based on measurements taken from the award-winning Wiivv app. All Wiivv products are designed to enhance and support your uniqueanatomy. The stack combines advanced capture technology, biomechanics research, CV, AI, ML, and a proprietary customization platform deigned to output on-demand digitally manufactured and 3DP products. Wiivv also partners with brands and creators to scale the rapid customization of their product categories powered by Wiivv Fit Technology. | $4M / Series A / Feb 08, 2017 | |
|
Swift Medical
|
Swift Medical is a digital wound care technology to improve the prevention, treatment, and management of wounds. From Capture to Claim: The world's most advanced and comprehensive wound care management software for the healthcare enterprise. Precise, consistent measurement, instant documentation and wound progression images with a smartphone. | $1.6M / Seed / Jan 24, 2017 | |
OMsignal
|
Omsignal manufactures bio-sensing clothing that connects to iPhones and iPads in real-time. Embedded sensors in the apparel monitor heart rate, breathing, and activity while the Omsignal app displays data in real-time on a mobile phone. OMsignal fits seamlessly into everyday life. It was founded in 2011 and is headquartered in Montréal, Canada. | $9.3M / Series B / Sep 19, 2016 | |
|
Algolux
|
Algolux is an award-winning AI software company delivering the industry’s most robust and scalable perception for all conditions, addressing both existing cameras and new designs through cloud-based tools and embedded software. The company was founded on groundbreaking research at the intersection of deep learning, computer vision, andcomputational imaging. Our computer vision and image optimization solutions address the mission-critical issue of safety for automotive ADAS, autonomous vehicles, fleets, autonomous mobile robots, and video security. | $450K / Convertible Note / Jan 16, 2016 | |
|
FitMyFoot
|
Wiivv (pronounced weave) is a technology company transforming footwear, apparel, and wearables for every human body, so that you can move and live your best. Wiivv Insoles and Sandals are created uniquely for you, based on measurements taken from the award-winning Wiivv app. All Wiivv products are designed to enhance and support your uniqueanatomy. The stack combines advanced capture technology, biomechanics research, CV, AI, ML, and a proprietary customization platform deigned to output on-demand digitally manufactured and 3DP products. Wiivv also partners with brands and creators to scale the rapid customization of their product categories powered by Wiivv Fit Technology. | $3.5M / Seed / Dec 03, 2015 | |
| See all 14 investments → | |||
Co-Investors
About Real Ventures
Real Ventures is an early-stage venture firm focused on serving daring entrepreneurs with the ambition to create successful, global companies. Since 2007, Real Ventures has dedicated itself to building the Canadian startup ecosystem on the belief that people, not money, build game-changing companies. Real Ventures provides stage-specific guidance,mentorship, and access to networks and resources to fast-track founders’ personal and company growth. Real Ventures manages $325 million across five funds and its active portfolio of 100+ companies is currently valued at $10 billion. www.realventures.com
Real Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Stokes
Managing Partner
|
|||
Sam Haffar
Partner
|
|||
|
Alan MacIntosh
Partner and Co-Founder
|
|||
Craig Follett
Limited Partner (Investor)
|
|||
Hamzah Nassif
Executive
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Alan MacIntosh invest in?
Alan MacIntosh invests primarily in Software, Health Care and Machine Learning startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alan MacIntosh's check size?
Alan MacIntosh typically joins rounds of $200k–$3.5M at Seed, $4M–$12M at Series A and $9.3M–$20M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alan MacIntosh participates in.
When did Alan MacIntosh last invest?
The most recent investment recorded for Alan MacIntosh closed in Aug 2021. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
